These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 27043676

  • 1. Prognostic Significance of 2-Deoxy-2-[18F]-Fluoro-D-Glucose PET/CT in Patients With Locally Advanced Esophageal Cancer Undergoing Neoadjuvant Chemoradiotherapy Before Surgery: A Nonparametric Approach.
    Giorgetti A, Pallabazzer G, Ripoli A, Solito B, Genovesi D, Lencioni M, Fabrini MG, D'Imporzano S, Pieraccini L, Marzullo P, Santi S.
    Medicine (Baltimore); 2016 Mar; 95(13):e3151. PubMed ID: 27043676
    [Abstract] [Full Text] [Related]

  • 2. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
    Kukar M, Alnaji RM, Jabi F, Platz TA, Attwood K, Nava H, Ben-David K, Mattson D, Salerno K, Malhotra U, Kanehira K, Gannon J, Hochwald SN.
    JAMA Surg; 2015 Jun; 150(6):555-62. PubMed ID: 25902198
    [Abstract] [Full Text] [Related]

  • 3. Prediction of Recurrence and Mortality of Locally Advanced Esophageal Cancer Patients Using Pretreatment F-18 FDG PET/CT Parameters: Intratumoral Heterogeneity, SUV, and Volumetric Parameters.
    Chang S, Kim SJ.
    Cancer Biother Radiopharm; 2016 Feb; 31(1):1-6. PubMed ID: 26844846
    [Abstract] [Full Text] [Related]

  • 4. Changes in Total Lesion Glycolysis Evaluated by Repeated F-18 FDG PET/CT as Prognostic Factor in Locally Advanced Esophageal Cancer Patients Treated with Preoperative Chemoradiotherapy.
    Chang S, Koo PJ, Kwak JJ, Kim SJ.
    Oncology; 2016 Feb; 90(2):97-102. PubMed ID: 26771676
    [Abstract] [Full Text] [Related]

  • 5. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H, Wroblewski K, Liao S, Kampalath R, Penney BC, Zhang Y, Pu Y.
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [Abstract] [Full Text] [Related]

  • 6. PET/CT in the evaluation of treatment response to neoadjuvant chemoradiotherapy and prognostication in patients with locally advanced esophageal squamous cell carcinoma.
    Yuan H, Tong DK, Vardhanabhuti V, Law SY, Chiu KW, Khong PL.
    Nucl Med Commun; 2016 Sep; 37(9):947-55. PubMed ID: 27145438
    [Abstract] [Full Text] [Related]

  • 7. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
    Piessen G, Petyt G, Duhamel A, Mirabel X, Huglo D, Mariette C.
    Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576
    [Abstract] [Full Text] [Related]

  • 8. Clinical implications of initial FDG-PET/CT in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
    Lee SJ, Kim JG, Lee SW, Chae YS, Kang BW, Lee YJ, Park JS, Choi GS.
    Cancer Chemother Pharmacol; 2013 May; 71(5):1201-7. PubMed ID: 23420438
    [Abstract] [Full Text] [Related]

  • 9. Predictive value of repeated F-18 FDG PET/CT parameters changes during preoperative chemoradiotherapy to predict pathologic response and overall survival in locally advanced esophageal adenocarcinoma patients.
    Kim SJ, Koo PJ, Chang S.
    Cancer Chemother Pharmacol; 2016 Apr; 77(4):723-31. PubMed ID: 26891957
    [Abstract] [Full Text] [Related]

  • 10. PET with Fluorodeoxyglucose F 18/Computed Tomography in the Clinical Management and Patient Outcomes of Esophageal Cancer.
    Kwee RM, Marcus C, Sheikhbahaei S, Subramaniam RM.
    PET Clin; 2015 Apr; 10(2):197-205. PubMed ID: 25829086
    [Abstract] [Full Text] [Related]

  • 11. Metabolic tumor width parameters as determined on PET/CT predict disease-free survival and treatment response in squamous cell carcinoma of the esophagus.
    Roedl JB, Halpern EF, Colen RR, Sahani DV, Fischman AJ, Blake MA.
    Mol Imaging Biol; 2009 Apr; 11(1):54-60. PubMed ID: 18769974
    [Abstract] [Full Text] [Related]

  • 12. Total Lesion Glycolysis Using ¹⁸F-FDG PET/CT as a Prognostic Factor for Locally Advanced Esophageal Cancer.
    Hong JH, Kim HH, Han EJ, Byun JH, Jang HS, Choi EK, Kang JH, Yoo IeR.
    J Korean Med Sci; 2016 Jan; 31(1):39-46. PubMed ID: 26770036
    [Abstract] [Full Text] [Related]

  • 13. 18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concomitant chemoradiotherapy.
    Usmanij EA, de Geus-Oei LF, Troost EG, Peters-Bax L, van der Heijden EH, Kaanders JH, Oyen WJ, Schuurbiers OC, Bussink J.
    J Nucl Med; 2013 Sep; 54(9):1528-34. PubMed ID: 23864719
    [Abstract] [Full Text] [Related]

  • 14. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
    Kauppi JT, Oksala N, Salo JA, Helin H, Karhumäki L, Kemppainen J, Sihvo EI, Räsänen JV.
    Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
    [Abstract] [Full Text] [Related]

  • 15. Good prediction of treatment responses to neoadjuvant chemoradiotherapy for esophageal cancer based on preoperative inflammatory status and tumor glucose metabolism.
    Li C, Lin JW, Yeh HL, Chuang CY, Chen CC.
    Sci Rep; 2021 Jun 02; 11(1):11626. PubMed ID: 34078965
    [Abstract] [Full Text] [Related]

  • 16. Prognostic Value of Pretherapeutic Tumor-to-Blood Standardized Uptake Ratio in Patients with Esophageal Carcinoma.
    Bütof R, Hofheinz F, Zöphel K, Stadelmann T, Schmollack J, Jentsch C, Löck S, Kotzerke J, Baumann M, van den Hoff J.
    J Nucl Med; 2015 Aug 02; 56(8):1150-6. PubMed ID: 26089549
    [Abstract] [Full Text] [Related]

  • 17. The predictive role of sequential FDG-PET/CT in response of locally advanced rectal cancer to neoadjuvant chemoradiation.
    Huh JW, Min JJ, Lee JH, Kim HR, Kim YJ.
    Am J Clin Oncol; 2012 Aug 02; 35(4):340-4. PubMed ID: 21422901
    [Abstract] [Full Text] [Related]

  • 18. Value of CT-PET after neoadjuvant chemoradiation in the prediction of histological tumour regression, nodal status and survival in oesophageal adenocarcinoma.
    Elliott JA, O'Farrell NJ, King S, Halpenny D, Malik V, Muldoon C, Johnston C, Reynolds JV.
    Br J Surg; 2014 Dec 02; 101(13):1702-11. PubMed ID: 25351460
    [Abstract] [Full Text] [Related]

  • 19. The value of ¹⁸F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy.
    Myslivecek M, Neoral C, Vrba R, Vomackova K, Cincibuch J, Formanek R, Koranda P, Zapletalova J.
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Jun 02; 156(2):171-9. PubMed ID: 22660205
    [Abstract] [Full Text] [Related]

  • 20. In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma.
    Hutchings M, Kostakoglu L, Zaucha JM, Malkowski B, Biggi A, Danielewicz I, Loft A, Specht L, Lamonica D, Czuczman MS, Nanni C, Zinzani PL, Diehl L, Stern R, Coleman M.
    J Clin Oncol; 2014 Sep 01; 32(25):2705-11. PubMed ID: 25071108
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.